Trial Profile

Study for PD-1 Inhibitor and Endostar in Previously Treated Advanced Non–Small-Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endostatin (Primary) ; Nivolumab (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Jun 2021 Status changed from not yet recruiting to recruiting.
08 Jun 2021 Results (n=35) assessing the efficacy and safety of nivolumab combined with recombinant human endostatin (rh-Endostatin) as second-line or later treatment for advanced NSCLC, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
30 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com